Highlights SynAct Pharma AB

Equities

SYNACT

SE0008241491

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
8.425 ^SEK	+1.44%		-5.34%	-4.59%

Jul. 01	SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon	CI
May. 31	SynAct Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon	Jul. 01	CI
SynAct Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 31	CI
SynAct Pharma AB Announces Outcomes of the Independent Audit of the 4-Week Resolve P2a Clinical Trial in Rheumatoid Arthritis	Mar. 10	CI
SynAct Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
SynAct Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 23	CI
SynAct Pharma Announces Additional Data from the Expand P2b Clinical Trial Supporting Continued Development of the Compound in Rheumatoid Arthritis	Feb. 22	CI
SynAct Pharma AB Announces Evaluation of the 4-Week RESOLVE P2a Clinical Trial in Moderate to Severe Active Rheumatoid Arthritis Patients with an incomplete Response to Methotrexate	Nov. 01	CI
SynAct Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-24	CI
SynAct Pharma AB Announces Additional Data from the Expands P2b Clinical Trial Further Supporting Efficacy and Activity seen in Patients with Elevated CRP	23-10-03	CI
SynAct Pharma AB Announces Additional Data from the EXPAND P2b Clinical Trial and Identifies Population with Responsiveness to Resomelagon	23-09-12	CI
Synact Pharma Announces Top Line Data from the 12-Week Expand P2b Clinical Trial in Severe Active Newly Diagnosed Rheumatoid Arthritis Patients	23-09-04	CI
SynAct Pharma AB Completes Dosing in Part A of Combined Phase 2A/B Resomelagon in Rheumatoid Arthritis (RA)	23-08-17	CI
SynAct Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
SynAct Pharma AB Completes Patient Recruitment for Part A of Combined Phase 2a/b RESOLVE Study of Resomelagon in Rheumatoid Arthritis	23-07-20	CI
SynAct Pharma AB Announces the Completion of Dosing in the Phase 2b Expand Study of Resomelagon in Early Severe Rheumatoid Arthritis Patients	23-07-14	CI
SynAct Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Synact Pharma AB Completes Patient Recruitment for Phase 2B Expands Study of Ap1189 in Early Severe Rheumatoid Arthritis	23-04-24	CI
SynAct Pharma AB Introduces Resomelagon as Generic Name for AP1189	23-03-30	CI
SynAct Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-17	CI
SynAct Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SynAct Pharma AB

Equities

SYNACT

SE0008241491

Highlights

Filters